papaverine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«123
  • ||||||||||  papaverine / Generic mfg.
    Clinical, Journal:  The Efficacy of Hydrodilatation for the Prevention of Vasospasm following Microsurgical Anastomosis. (Pubmed Central) -  Jul 28, 2022   
     Hydrodilatation and papaverine application were both effective in preventing vasospasm following microsurgical intervention but papaverine caused slightly less damage to the endothelial lining and less edema in the tunica adventitia when compared with the hydrodilatation. Hydrodilatation group showed a vasodilatory effect that was statistically similar to that of papaverine, which has a proven efficacy.
  • ||||||||||  papaverine / Generic mfg.
    Journal:  Can Isoquinoline Alkaloids Affect Platelet Aggregation in Whole Human Blood? (Pubmed Central) -  Jul 26, 2022   
    Papaverine and bulbocapnine were the most potent compounds with biologically relevant IC values of 26.9 ± 12.2 μM and 30.7 ± 5.4 μM, respectively...Bulbocapnine was an exception. It proved to be a promising antiplatelet molecule, which may have biologically relevant effects.
  • ||||||||||  Synribo (omacetaxine mepesuccinate) / Stragen, Teva
    Review, Journal:  The naturally-derived alkaloids as a potential treatment for COVID-19: A scoping review. (Pubmed Central) -  Jul 24, 2022   
    The possible ability of alkaloids to inhibit protein targets and to reduce inflammatory markers show the potential for development of new treatment strategies against COVID-19. However, more high quality analyses/reviews in this field are necessary to firmly establish the effectiveness/safety of the alkaloids here described.
  • ||||||||||  tadalafil / Generic mfg.
    Review, Journal:  Erectile Dysfunction: Key Role of Cavernous Smooth Muscle Cells. (Pubmed Central) -  Jul 23, 2022   
    Despite this, studies that consolidate the understanding of its pathophysiological process contribute to the discovery of new more efficient drugs for the treatment of erectile dysfunction. In this sense, in the present work an extensive survey was carried out of the mechanisms already consolidated and the most recent ones related to the development of erectile dysfunction.
  • ||||||||||  papaverine / Generic mfg.
    Journal:  Papaverine, a promising therapeutic agent for the treatment of COVID-19 patients with underlying cardiovascular diseases (CVDs). (Pubmed Central) -  Jun 22, 2022   
    The ability of papaverine to treat COVID-19 has become more promising when the results of some extensive screenings showed the strong ability of this compound to inhibit the cytopathic effects of SARS-CoV-2 with EC of 1.1 μM. Having several therapeutic effects along with desired safety profile raises this hypothesis that papaverine could be a promising compound for the suppression of SARS-CoV-2 and prevention of ischemia/vasoconstriction-related complications in COVID-19 disease, especially in patients with underlying cardiovascular diseases (CVDs).
  • ||||||||||  papaverine / Generic mfg.
    Trial completion date, Trial primary completion date:  Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases (clinicaltrials.gov) -  Jun 10, 2022   
    P1,  N=24, Recruiting, 
    Having several therapeutic effects along with desired safety profile raises this hypothesis that papaverine could be a promising compound for the suppression of SARS-CoV-2 and prevention of ischemia/vasoconstriction-related complications in COVID-19 disease, especially in patients with underlying cardiovascular diseases (CVDs). Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  morphine sulphate / Generic mfg., papaverine / Generic mfg., captopril / Generic mfg.
    Journal:  Increasing DESI-MS Ion Signal by Plasma Treatment. (Pubmed Central) -  Jun 4, 2022   
    Under optimal treatment conditions, an improved ion signal intensity is observed without any fragmentation, decomposition, or chemical changes. Ion signals are increased possibly by both increased ionization through protonation of molecules and enhanced subsequent desorption during DESI analysis.
  • ||||||||||  Miostat (carbachol) / Novartis
    Journal:  Dual Inhibition of Phosphodiesterase and Ca Channels Explains the Medicinal Use of Balanites aegyptiaca (L.) in Hyperactive Gut Disorders. (Pubmed Central) -  May 15, 2022   
    The inhibitory effects of B. aegyptiaca on PDE were further confirmed when the pre-incubated extract shifted the isoprenaline-mediated relaxation curves (CRCs) towards the left, similar to papaverine, whereas the CCB-like effect was confirmed when the pre-incubated tissues with B. aegyptiaca caused deflection in the Ca CRCs towards the right, constructed in Ca free medium with suppression of the maximum response. Thus, this study provides detailed, mechanistic support for the medicinal use of B. aegyptiaca in the treatment of hyperactive gut disorders.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Journal:  Stratification by Race Reveals Disparate Vascular Toxicity in Response to Anti-Cancer Therapies. (Pubmed Central) -  May 14, 2022   
    Our findings reveal disparate effects of CTx agents on microvascular endothelial function from B and NHW patients. This raises the possibility that microvascular dysfunction may contribute to the known disparities in adverse CV clinical outcomes of cancer patients and potentially other CV pathologies (e.g., disparities in adverse events associated with PTX-eluting stents.) Future work should differentiate between biological/genetic vs. social/environmental contribution to observed microvascular responses to CTx.
  • ||||||||||  papaverine / Generic mfg.
    Enrollment open, Combination therapy:  Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer (clinicaltrials.gov) -  Apr 25, 2022   
    P1,  N=28, Recruiting, 
    This raises the possibility that microvascular dysfunction may contribute to the known disparities in adverse CV clinical outcomes of cancer patients and potentially other CV pathologies (e.g., disparities in adverse events associated with PTX-eluting stents.) Future work should differentiate between biological/genetic vs. social/environmental contribution to observed microvascular responses to CTx. Not yet recruiting --> Recruiting
  • ||||||||||  papaverine / Generic mfg., tadalafil / Generic mfg.
    Erectile Function 5-years Following Successful Penis Transplantation (Room 228) -  Apr 10, 2022 - Abstract #AUA2022AUA_2322;    
    Until recently he had been using daily Tadalafil 5mg with good effect but had subsequently noted 30-40% decline in erectile quality...The Trimix IUG are composed of 7.5mg Papaverine, 1mg Phentolamine, and varying amounts of Alprostadil (250mcg to 1000mcg)...There were initial venous leak demonstrable, however, at higher doses, there is diminished venous leak and greater rigidity achieved. Conclusions : Our data is the first to demonstrate and characterize successful achievement of erectile function 5-years after Genito-urinary composite allotransplantation.
  • ||||||||||  papaverine / Generic mfg.
    Trial initiation date, Combination therapy:  Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer (clinicaltrials.gov) -  Jan 27, 2022   
    P1,  N=28, Not yet recruiting, 
    Conclusions : Our data is the first to demonstrate and characterize successful achievement of erectile function 5-years after Genito-urinary composite allotransplantation. Initiation date: Dec 2021 --> Mar 2022
  • ||||||||||  papaverine / Generic mfg.
    Trial completion:  Effect of Papaverine on Renal Artery Blood Flow Volume (clinicaltrials.gov) -  Apr 19, 2021   
    P4,  N=96, Completed, 
    Initiation date: Dec 2021 --> Mar 2022 Recruiting --> Completed
  • ||||||||||  papaverine / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Papaverine vs Heparin for Peripheral Arterial Catheter Patency in Pediatric Patients (clinicaltrials.gov) -  Apr 13, 2021   
    P4,  N=100, Completed, 
    Recruiting --> Completed Recruiting --> Completed | Trial completion date: Apr 2021 --> Oct 2020 | Trial primary completion date: Apr 2021 --> Oct 2020
  • ||||||||||  papaverine / Generic mfg.
    Trial completion date:  Prostatic Hyperplasia Treatment and Cancer Prevention (clinicaltrials.gov) -  Feb 25, 2021   
    P1,  N=40, Not yet recruiting, 
    Recruiting --> Completed | Trial completion date: Apr 2021 --> Oct 2020 | Trial primary completion date: Apr 2021 --> Oct 2020 Trial completion date: Sep 2021 --> Dec 2021
  • ||||||||||  papaverine / Generic mfg.
    Trial primary completion date:  Effect of Papaverine on Renal Artery Blood Flow Volume (clinicaltrials.gov) -  Jan 5, 2021   
    P4,  N=96, Recruiting, 
    Trial completion date: Sep 2021 --> Dec 2021 Trial primary completion date: Oct 2020 --> Mar 2021
  • ||||||||||  papaverine / Generic mfg.
    Trial completion date, Trial primary completion date:  Prostatic Hyperplasia Treatment and Cancer Prevention (clinicaltrials.gov) -  May 20, 2020   
    P1,  N=40, Not yet recruiting, 
    Active, not recruiting --> Completed Trial completion date: Jul 2019 --> Sep 2021 | Trial primary completion date: May 2019 --> Jul 2021
  • ||||||||||  papaverine / Generic mfg.
    Enrollment open:  Effect of Papaverine on Renal Artery Blood Flow Volume (clinicaltrials.gov) -  Dec 1, 2019   
    P4,  N=96, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  papaverine / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  Prostatic Hyperplasia Treatment and Cancer Prevention (clinicaltrials.gov) -  Aug 15, 2018   
    P1,  N=40, Not yet recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Nov 2018 --> Jul 2019 | Trial primary completion date: Sep 2018 --> May 2019 | Initiation date: Jul 2018 --> Oct 2018
  • ||||||||||  papaverine / Generic mfg.
    Trial initiation date, Trial primary completion date:  Prostatic Hyperplasia Treatment and Cancer Prevention (clinicaltrials.gov) -  Aug 30, 2017   
    P,  N=40, Not yet recruiting, 
    Trial completion date: Nov 2018 --> Jul 2019 | Trial primary completion date: Sep 2018 --> May 2019 | Initiation date: Jul 2018 --> Oct 2018 Initiation date: Apr 2017 --> Sep 2017 | Trial primary completion date: Jun 2017 --> Feb 2018
  • ||||||||||  metamizole / Generic mfg., papaverine / Generic mfg.
    New P3 trial:  Optimal Analgesia in Acute Gastroenteritis (clinicaltrials.gov) -  Mar 18, 2016   
    P3,  N=15, Terminated, 
  • ||||||||||  papaverine / Generic mfg.
    Trial completion:  Pharmacokinetics of Pavaverine After Intraluminal Administration (clinicaltrials.gov) -  Jun 2, 2013   
    P=N/A,  N=12, Completed, 
    Active, not recruiting --> Completed Not yet recruiting --> Completed
  • ||||||||||  papaverine / Generic mfg.
    Trial initiation date:  Pharmacokinetics of Pavaverine After Intraluminal Administration (clinicaltrials.gov) -  Jun 3, 2012   
    P=N/A,  N=12, Completed, 
    Not yet recruiting --> Completed Initiation date: Oct 2011 --> Oct 2012